Quanterix Granted Breakthrough Device Designation From U.S. FDA For Blood-Based P-Tau 217 Test For Alzheimer’s Disease
Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, announced today that its Simoa® phospho-Tau 217 (p-Tau 217) blood test has been granted Breakthrough Device designation…